Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grace TherapeuticsGRCE 31 3-Year EBITDA Growth Rate is 35.00% as of Mar. 2026, which is 94% above its 10-year median of 18.00. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, Grace Therapeutics ranks better than 73.33% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 34.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Grace Therapeutics was 57.50% per year. The lowest was -31.00% per year. And the median was 18.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Grace Therapeutics 3-Year EBITDA Growth Rate Related Terms
GRCE vs PDSB, HYPD, RNXT: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Grace Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grace Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Grace Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Grace Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.00% mean?
Grace Therapeutics (GRCE) has a 3-Year EBITDA Growth Rate of 35.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Grace Therapeutics and its competitors. This is 94% above median its historical median of 18.00. According to the industry distribution chart, Grace Therapeutics ranks #303 out of 1136 companies in the Biotechnology industry, placing it in the top 26.7%.
Is Grace Therapeutics' 3-Year EBITDA Growth Rate too high?
Grace Therapeutics' current 3-Year EBITDA Growth Rate of 35.00% is 94% above median its 10-year median of 18.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Grace Therapeutics' value of 35.00% is 135.7% above this industry median. Based on the distribution chart, Grace Therapeutics ranks #303 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' 3-Year EBITDA Growth Rate compare to PDSB and HYPD?
According to the Biotechnology industry distribution chart, Grace Therapeutics ranks #303 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Grace Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Grace Therapeutics' value of 35.00% is 135.7% above this benchmark. While the company's 10-year median is 18.00 vs. the industry median of 14.85, Grace Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grace Therapeutics's current 3-Year EBITDA Growth Rate of 35.00% is 135.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Grace Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grace Therapeutics's current 3-Year EBITDA Growth Rate is 35.00%, which is 94% above median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current 3-Year EBITDA Growth Rate of 35.00%. The current 3-Year EBITDA Growth Rate is 35.00%, which is 94% above median its 10-year median of 18.00 and 135.7% above the Biotechnology industry median of 14.85. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current 3-Year EBITDA Growth Rate is 35.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score
Get the complete analysis for GRCE
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRCE has been successfully added to your 
